Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20 ...

According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of ...

MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

In some good news for the US vaccines developer, whose stock has fallen 66% in the past 12 months, Moderna on Friday ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Moderna (MRNA) to $38 from $70 and keeps an Equal Weight rating on the ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough ... That seems like a very reasonable price when you consider commercial-stage biotech stocks tend to trade for mid-single-digit ...

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) ...